ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Liping Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0070-9728; OpenAlex author ID A5101854040. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2020: 2 papers

Papers 2

LncRNA LOXL1-AS1/miR-28-5p/SEMA7A axis facilitates pancreatic cancer progression. Last author DOI 10.1002/cbf.3449 ↗
LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway. Co-author DOI 10.1186/s12935-020-01366-w ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Cheng Guo Ma · 2 shared papers, 2020 · strength 0.32
- Paper LncRNA LOXL1-AS1/miR-28-5p/SEMA7A axis facilitates pancreatic cancer progression. DOI 10.1002/cbf.3449 ↗
- Paper LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway. DOI 10.1186/s12935-020-01366-w ↗
Yongcun Liu · 2 shared papers, 2020 · strength 0.32
- Paper LncRNA LOXL1-AS1/miR-28-5p/SEMA7A axis facilitates pancreatic cancer progression. DOI 10.1002/cbf.3449 ↗
- Paper LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway. DOI 10.1186/s12935-020-01366-w ↗
Yuan Shao · 1 shared paper, 2020 · strength 0.16
- Paper LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway. DOI 10.1186/s12935-020-01366-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.